<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082835</url>
  </required_header>
  <id_info>
    <org_study_id>0081122</org_study_id>
    <nct_id>NCT01082835</nct_id>
  </id_info>
  <brief_title>Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study</brief_title>
  <acronym>JZQG</acronym>
  <official_title>Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Jangzhuo Qinggan prescription and irbesartan in the treatment of essential
      hypertension(Hepatogastric Damp-heat), randomized, parallel-controlled, multi-center clinical
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charged by the five research centers in line with traditional Chinese medicine hepatogastric
      Damp-heat syndrome 240 cases have hypertension, and overweight, as well as blood lipid
      disorders or diabetes were randomly divided into Chinese herbal compound Jiangzhuo Qinggan
      prescription group and western medicine irbesartan group.The treatment groups were compared
      4-week step-down and regulation of blood lipids, blood sugar effect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>the group of Jiangzhuo Qinggan prescription</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>the group of irbesartan</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Combined metabolic syndrome in patients with essential hypertension
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consistent with diagnosed hypertension, blood pressure, for 1-2 grade.

          2. Aged 18-65 years old.

          3. Body mass index (BMI) ≥ 24kg/m2, but &lt;35 kg/m2.

          4. Waist circumference ≥ 85cm (male) or waist circumference ≥ 80cm (women).

          5. Comply with any of the following 3 : triglyceride (TG) elevated levels of:&gt; 150mg/dl
             (1.7mmol / l), or has received appropriate treatment; high-density lipoprotein -
             cholesterol (HDL-C) levels reduced: Men &lt;40mg/dl (0.9mmol / l), women &lt;50mg/dl
             (1.1mmol / l), or has received appropriate treatment; fasting plasma glucose (FPG)
             increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or
             have received appropriate treatment.

          6. Hepatogastric Damp-heat syndrome differentiation.

          7. To sign informed consent.

        Exclusion Criteria:

          1. Has been used to control lipids, blood sugar drugs, but use the time for those below
             the 1 month.

          2. Nearly 3 months, weight loss ≥ 5%.

          3. Suffering from congenital heart disease, rheumatic heart disease, congestive heart
             failure, unstable angina, and had a myocardial infarction, percutaneous transluminal
             coronary angioplasty (PTCA) or off-line clinical significance of arrhythmia.

          4. Bilateral renal artery stenosis, solitary kidney, serum creatinine&gt; 133μmol / L .

          5. Active liver disease, history of chronic persistent hepatitis, ALT&gt; upper limit of
             normal.

          6. Peptic ulcer or malabsorption syndrome .

          7. With insulin-treated diabetes.

          8. There is a history of appetite or abuse of laxatives by hyperthyroidism.

          9. Pregnancy, pregnancy or breast-feeding women to prepare.

         10. For those who are allergic Chinese medicine, allergic people.

         11. Mentally ill.

         12. Hyperkalemia in patients.

         13. Cancer.

         14. Occurred within the past 6 months who had a stroke or transient ischemic attack (TIA).

         15. Nearly 3 months in patients receiving other clinical studies.

         16. Alcohol and / or psychoactive substances, drug abuse and dependency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fenglian Li, PHD</last_name>
    <phone>0086-010-88001402</phone>
    <email>lfm565@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Medical University ,Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weixing Lu</last_name>
      <phone>0086-013601067938</phone>
      <email>weixinglu918@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Medical University,Dongfang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qian Lin</last_name>
      <phone>0086-013910565673</phone>
      <email>dfluyao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Academy of Chinese Medical Sciences,Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Zhou</last_name>
      <phone>0086-015101016416</phone>
      <email>tiantianlanzhouqiang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Fu Wai Cardiovascular Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianfeng Huang</last_name>
      <phone>0086-010-88396403</phone>
      <email>jianfhuang918@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital University of Medical, Anzhen Hospital</name>
      <address>
        <city>Beijng</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenqiu Yu</last_name>
      <phone>0086-010-64456577</phone>
      <email>yuzhenqiu@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guang'anmen Hospital</name_title>
    <organization>China Academy of Chinese Medical Sciences</organization>
  </responsible_party>
  <keyword>Chinese herbs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

